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 Extreme caution is needed before scale-up of antenatal 
corticosteroids to reduce preterm deaths in low-income settings
The great American epidemiologist Bill Silverman 
taught us that the road to hell is paved with good 
intentions. From 1942, during a 12-year period, more 
than 10 000 infants were blinded through retinopathy 
of prematurity because paediatricians recommended 
a minor increase in the concentration of supplemental 
oxygen for preterm infants in incubators.1 Later, “untold 
thousands of premature infants succumbed in the ﬁ rst 
few days of life because incubator temperatures were 
set slightly too low (to avoid overheating)”.2 Indeed, 
Silverman’s trial of adrenocorticotrophic hormone to 
treat retinopathy of prematurity showed no beneﬁ t and 
an increased death rate in the intervention group. He 
warned that we need trial evidence for any new preterm 
intervention. No shortcuts can be used—care of the 
preterm infant is a delicate and integrated process.  
Recently, antenatal corticosteroid treatment has 
been widely promoted to reduce preterm deaths in 
developing countries. On the face of it, the argument 
seems to be persuasive. Worldwide, 15 million infants 
are born prematurely every year, and south Asia accounts 
for two-thirds and Africa for three-quarters of deaths in 
these infants.3 The 2013 State of the World’s Mothers 
report says: “Prenatal corticosteroids cost as little as 
51 cents per treatment… are ready for rapid scale-up 
now…using skilled birth attendants…and could save 
340 000 newborn lives each year”.4 This estimate does 
not come from trials but rather from a Lives Saved 
Analysis tool.4 
The evidence is far more nuanced. A systematic 
review of 21 studies in high-income and middle-
income country hospitals, which included a total of 
3885 women and 4269 infants, showed that one course 
of corticosteroids to accelerate fetal lung maturation 
in women at risk of preterm birth reduced neonatal 
deaths by 31% (relative risk [RR] 0·69, 95% CI 0·58–0·81; 
in 18 studies of 3956 infants) and respiratory distress 
syndrome by 34% (0·66, 95% CI 0·59–0·73; in 21 studies 
of 4038 infants).5 Nonetheless, the statement made 
by the Healthy Newborn Network that “administering 
antenatal steroids to a mom in preterm labour, helps 
her baby speed up lung development, reducing the risk 
of newborn death by more than 50% in low-resource 
facilities”—is speculative. The clamour to roll out a so-
called magic bullet treatment must be resisted until 
three crucial questions have been answered.
The ﬁ rst of these questions is whether antenatal 
corticosteroids actually work for mothers and infants 
at 33 weeks’ gestation or less in poor populations? All 
studies in the systematic review were from hospitals 
in which infants had access to ”level 2” special care: 
24-h availability of skilled nursing; thermal stability; 
monitoring of blood gases, glucose, electrolytes, 
infection indicators, and bilirubin; apnoea alarms; oxygen 
and ventilatory support; and antibiotics and other 
essential drugs for infection and shock. Similar reductions 
in case-fatality rate are highly unlikely in settings where 
level 2 care is not available. Coverage of good-quality 
level 2 care in low-income settings is tiny—few facilities 
exist outside capital cities. One study of 1000 low-
birthweight infants in Dhaka, Bangladesh, showed that 
even in a teaching hospital that provided level 2 care, 
three-quarters of neonates born at less than 33 weeks’ 
gestation died during the neonatal period.6 The causes 
of death were manifold and not just attributable to 
respiratory distress. Indeed, respiratory distress syndrome 
might be less prevalent in poor countries than in wealthy 
nations because intrauterine growth retardation 
causes fetal cortisol concentrations to rise, which might 
accelerate the production of lung surfactant. 
The second crucial question asks whether safety issues 
exist in poor settings. If steroids are given to millions of 
women in preterm labour in poor populations, can we 
be sure that there will be no signiﬁ cantly increased risk of 
maternal sepsis, perinatal death, or childhood disability? 
The 2006 systematic review showed that, from eight 
trials and 1003 women with data for puerperal sepsis, 
57 of 496 treated mothers had sepsis, compared 
with 44 of 507 controls (RR 1·35, 95% CI 0·93–1·95). 
More worrying is the evidence from trials that used 
dexamethasone (the low-cost treatment recommended 
for scale-up), which signiﬁ cantly increased both 
puerperal sepsis (RR 1·74, 95% CI 1·04–2·89; in four 
trials of 536 women) and fever that needed antibiotics 
(2·05, 1·14–3·69; in one trial of 118 women), in 
comparatively wealthy populations.7 These ﬁ ndings 
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ring alarm bells for scale-up in populations in which 
the prevalence of malnutrition and the risk of sepsis are 
much higher and access to antibiotics is low. In infants 
born at a gestation of at least 36 weeks, an almost 
signiﬁ cant trend was recorded towards an increase in 
combined fetal and neonatal death (RR 3·25, 95% CI 
0·99–10·66; in two studies of 498 infants). 
Another major concern is that a substantially increased 
risk of disability can occur in cases where preterm survival 
is accompanied by suboptimum care. Historically, 
outcomes for preterm infants born at weights of less 
than 1500 g in developed countries showed that 
mortality rates and the prevalence of major disability in 
survivors were very high until after 1960 when level 2 
care improved on a wide scale. 
The third crucial question is whether there is any 
evidence of beneﬁ t for the great majority of preterm 
infants born at more than 33 weeks? A recent 
working paper for the UN Commission on Life-Saving 
Commodities for Women and Children promotes scale-
up of steroids by suggesting “the eﬀ ect is greatest 
between 31 weeks and 36 weeks gestation” although 
no evidence shows an eﬀ ect beyond 33 weeks.7 Three-
quarters of the 12·6 million preterm infants worldwide 
each year are born after 33 completed weeks of gestation. 
In this group, the systematic review of antenatal 
steroids5 showed no reduction in fetal or newborn 
deaths. For deaths in newborn babies alone, there was 
no beneﬁ t for babies born at 34 weeks or more (RR 1·58, 
95% CI 0·71–3·50; two studies, 808 infants) or for babies 
born at 36 weeks or more (2·62, 95% CI 0·77–8·96, 
three studies, 514 infants). Moreover, there was no 
reduction in respiratory distress at more than 34 weeks, 
as we might expect from the timing of maturation of 
surfactant production. For these reasons, the American 
Academy of Obstetrics and Gynecology and the British 
Royal College of Obstetrics and Gynaecology both 
recommend steroid treatment for mothers only up to 
33 weeks’ gestation.
With no evidence of beneﬁ t after 33 weeks in any 
setting, questionable beneﬁ t at less than 33 weeks in 
poor populations, potential risks of sepsis in mothers, 
and unknown disability levels in babies in cases where 
level 2 care standards are not met, we urge extreme 
caution. Millions of mothers in poor populations could 
soon be given steroid injections each year which carry 
risks that could substantially exceed the beneﬁ ts. 
We support the existing recommendation to restrict 
single-dose antenatal steroids to mothers who are at 
33 weeks’ gestation or less, in preterm labour, and with 
easy access to good quality, round-the-clock level 2 care. 
We need clear evidence for beneﬁ t in other settings. 
One multicountry trial at established research sites 
in Argentina, Guatemala, Kenya, India, Pakistan, and 
Zambia is underway.8 Other trials in poor and inaccessible 
populations are needed before we can be certain of the 
risk– beneﬁ t ratio. 
No quick ﬁ x exists to ensure preterm survival without 
serious disability. The global priority remains greater 
coverage of round-the-clock provision of high-quality 
level 2 care. The scope for low-cost innovation in district 
facilities is tremendous—eg, kangaroo care, the use of 
nursing aides to support scarce nursing staﬀ , simple 
technology for blood sugar and bilirubin estimation, 
electricity-free syringe pumps, and low-cost incubators 
for babies too ill to manage skin-to-skin care. However, 
technology and drugs alone are dangerous without the 
provision and retention of skilled and motivated staﬀ —
the biggest challenge of all.
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